Tag: trials

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to the two nephrology trials selected for funding by the Accelerating Clinical Trials (ACT) Consortium!

 

The objective of this request for applications was to fund partnerships with Canadian-controlled biotechnology companies and ACT/AEC Network clinical trialists. The consortium received 30 applications and selected 6 projects for funding up to $400,000 each.

Each proposal underwent a targeted peer review process where each application was reviewed by a total of 10 independent reviewers – 5 reviewers with experience in clinical trials and 5 reviewers with experience in biotechnology.

We are proud to announce that 2 of the 6 projects selected were endorsed by CNTN.

 

Dr. Michael Walsh, 
Dr. Peter Margetts, 
Dr. Pavel Roshanov – EQUAL Dialysis: Evaluation of Qidni Urea And metabolite cLearance in maintenance Dialysis

Biotech: Qidni

 

Dr. Matthew James, Dr. Neesh Pannu, Dr. Daniel Muruve – PONTIAC: Prevention of Nephrotoxin-induced AKI with Cilastatin Trial

Biotech: Arch Biopartners Inc. 

 

 

You can see the full list of awarded trials here

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to Drs. Sam Silver, Amber Molnar and Ann Young and teams for being selected for funding by the Accelerating Clinical Trials (ACT) Consortium! Stream 1 for this request for applications was dedicated to novel trial designs. With a total funding pool of $1.5 million, 2 of the 8 trials selected were CNTN endorsed trials:

 

Dr. Samuel Silver (Kingston, ON; Queens University) and Dr. Amber Molnar (Hamilton, ON; McMaster University): Dial-Bicarb: The Dial-Bicarb Trial investigates dialysate bicarbonate levels
 

Dr. Ann Young (Toronto, ON; Unity Health Toronto and St. Michael’s Hospital): KidneyCare Outreach: Vanguard phase of a population-based randomized clinical trial to strengthen kidney care delivery for patients at high risk of kidney failure

 

You can see the full list of awarded trials here

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to Dr. Michael Walsh and Dr. Amit Garg and teams for being selected for funding by the Canadian Institutes for Health Research (CIHR)’s Accelerating Clinical Trials (ACT) Consortium! Of the 43 trials that applied for funding, 2 of the 11 trials selected were CNTN endorsed trials: 

 

Dr. Amit Garg (London, ON; Western University and the London Health Sciences Centre): Effect of a Multi-Component Quality Improvement Intervention on Patient Access to Kidney Transplantation and Living Kidney Donation (EnAKT-LKD)
 

Dr. Michael Walsh (Hamilton, ON; McMaster University and the Population Health Research Institute): Aldosterone blockade for Health Improvement Evaluation in End-stage renal disease (ACHIEVE) 

 

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.
 

This most recent call for proposals was designed to support ongoing and active, Canadian-led, high-impact RCTs that required additional funding for successful completion. All recipients of this ACT grant will publicly report their results by January 15, 2025. 

 

We look forward to learning their results!